Evotec SE
EVO- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001412558
No open-market purchases or sales by Evotec SE insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $9.07M in total; no superinvestor holds it.
Other share classesEVOTF
13F holders, Q3 2023
Institutional positions in Evotec SE as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 24
- +4 vs. Q2 2023
- Shares held
- 1.22M
- −162.2K (−11.8%) vs. Q2 2023
- Total value
- $12.0M
- −$3.44M (−22.2%) vs. Q2 2023
- New holders
- 5
- 8 more added
- Sold out
- 1
- 4 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting EVO on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 34 | $9.07M |
| Q1 2026 | 46 | $20.3M |
| Q4 2025 | 44 | $30.4M |
| Q3 2025 | 37 | $35.9M |
| Q2 2025 | 37 | $40.5M |
| Q1 2025 | 25 | $30.4M |
| Q4 2024 | 26 | $36.9M |
| Q3 2024 | 24 | $29.6M |
| Q2 2024 | 28 | $35.0M |
| Q1 2024 | 20 | $38.7M |
| Q4 2023 | 28 | $66.5M |
| Q3 2023 | 24 | $12.0M |
| Q2 2023 | 20 | $15.4M |
| Q1 2023 | 19 | $14.5M |
| Q4 2022 | 22 | $21.1M |
| Q3 2022 | 22 | $43.5M |
| Q2 2022 | 21 | $57.3M |
| Q1 2022 | 22 | $83.3M |
| Q4 2021 | 20 | $157.3M |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Evotec SE; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Federated Hermes, Inc. | 578,533 | $5.71M | 0.02% | −171,467−22.9% | Reduced |
| Millennium Management LLC | 231,062 | $2.28M | 0.00% | +2,108+0.9% | Added |
| Zurcher Kantonalbank (Zurich Cantonalbank) | 202,368 | $2.00M | 0.01% | −13,300−6.2% | Reduced |
| Morgan Stanley | 68,108 | $672.2K | 0.00% | +15,286+28.9% | Added |
| DCF Advisers, LLC | 49,047 | $484.1K | 0.34% | +6,309+14.8% | Added |
| Citadel Advisors LLC | 25,754 | $254.2K | 0.00% | +12,254+90.8% | Added |
| Cetera Investment Advisers | 25,638 | $253.0K | 0.00% | +25,638 | New |
| Optiver Holding B.V. | 10,874 | $107.3K | 0.00% | −23,082−68.0% | Reduced |
| BlackRock Inc. | 9,556 | $94.3K | 0.00% | +4,118+75.7% | Added |
| Bank of America Corp | 5,244 | $51.8K | 0.00% | +795+17.9% | Added |
| FMR LLC | 4,486 | $44.3K | 0.00% | 00.0% | Unchanged |
| Briaud Financial Planning, Inc | 2,160 | $21.0K | 0.02% | +2,160 | New |
| UBS Group AG | 1,839 | $18.2K | 0.00% | −5,486−74.9% | Reduced |
| Signaturefd, LLC | 542 | $5.35K | 0.00% | +398+276.4% | Added |
| Washington Trust Co | 421 | $4.16K | 0.00% | 00.0% | Unchanged |
| US Bancorp | 250 | $2.47K | 0.00% | 00.0% | Unchanged |
| Clearstead Advisors, LLC | 150 | $1.48K | 0.00% | +150 | New |
| JPMorgan Chase & Co | 135 | $1.33K | 0.00% | +135 | New |
| Royal Bank of Canada | 100 | $1.00K | 0.00% | 00.0% | Unchanged |
| Advisor Group Holdings, Inc. | 101 | $996 | 0.00% | +83+461.1% | Added |
| Lindbrook Capital, LLC | 72 | $711 | 0.00% | 00.0% | Unchanged |
| Parallel Advisors, LLC | 70 | $691 | 0.00% | 00.0% | Unchanged |
| Bell Investment Advisors, Inc | 66 | $652 | 0.00% | 00.0% | Unchanged |
| Qube Research & Technologies Ltd | 10 | $99 | 0.00% | +10 | New |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −18,310−100.0% | Sold out |